These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. De A; Duseja A J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182 [TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Takaki A; Kawai D; Yamamoto K Int J Mol Sci; 2014 Apr; 15(5):7352-79. PubMed ID: 24786095 [TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Hochreuter MY; Dall M; Treebak JT; Barrès R Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120 [TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M Gene; 2020 Jun; 742():144549. PubMed ID: 32184169 [TBL] [Abstract][Full Text] [Related]
19. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876 [TBL] [Abstract][Full Text] [Related]
20. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]